+

WO2004037270A1 - Regulation de cyclooxygenase avec des liposomes pg - Google Patents

Regulation de cyclooxygenase avec des liposomes pg Download PDF

Info

Publication number
WO2004037270A1
WO2004037270A1 PCT/CA2003/001622 CA0301622W WO2004037270A1 WO 2004037270 A1 WO2004037270 A1 WO 2004037270A1 CA 0301622 W CA0301622 W CA 0301622W WO 2004037270 A1 WO2004037270 A1 WO 2004037270A1
Authority
WO
WIPO (PCT)
Prior art keywords
use according
bodies
cox
condition
mammalian
Prior art date
Application number
PCT/CA2003/001622
Other languages
English (en)
Inventor
Anthony E. Bolton
Arkady Mandel
Niamh Moran
Original Assignee
Vasogen Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Limited filed Critical Vasogen Ireland Limited
Priority to AU2003275842A priority Critical patent/AU2003275842A1/en
Publication of WO2004037270A1 publication Critical patent/WO2004037270A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to the enzyme cyclooxygenase, and methods for its regulation in the mammalian body. More specifically, it relates to a process and composition for administration to a mammalian subject for modulating expression of the expression of the cyclooxygenase (COX)-2 gene. Such modulation can be advantageously employed in the overall well-being of the mammalian body, especially in alleviation of pain.
  • COX cyclooxygenase
  • Cyclooxygenase (COX, also referred to as prostaglandin endoperoxide H synthase, PGHS) is the rate-limiting enzyme in prostaglandin synthesis in the body, and exists as two isof ⁇ rms, COX-1 and COX-2. They have two enzymatic functions, namely a cyclooxygenase function that converts arachidonic acid to prostaglandin G 2 (PGG 2 ), with formation of an oxygen- containing ring structure, and a peroxidase activity that converts PGG 2 to prostaglandin H 2 (PGH 2 ). PGH 2 in turn acts as the precursor of various
  • eicosanoids including PGE 2 , PGF 2 ⁇ , PGD 2 , prostacyclin and thromboxane A 2 .
  • Eicosanoids are commonly known as pivotal regulators of immune and inflammatory processes (Gong C, et al, Brain Res. 2001 901 :38-46). It is known that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) block the enzymatic activity of both isoforms. This is at least part of the underlying mechanism of the anti-inflammatory activity of aspirin and other NSAIDs, prostaglandins being, in general, inflammation stimulating substances.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • COX-1 and COX-2 are encoded by separate genes located on different chromosomes.
  • the COX-1 gene is larger, and its structure facilitates continuous transcription of a stable message, so that it is a constitutive, housekeeping enzyme, present in most cells and tissues.
  • the COX-2 gene is smaller, and is consistent with its characterization as an immediate-early stage gene that is rapidly upregulated during inflammation and other pathological processes. COX-2 normally is not detectable in most tissues, but can be induced by mitogens, cytokines and certain inflammatory agents.
  • a consequence of the over expression or over-activity of either or both of COX-1 and COX-2 is pain.
  • the source or cause of the pain may be inflammation, tissue damage through injury, muscle damage through injury, over-exertion, etc., burns, chemical exposure, toxic substance ingestion or the like, all of which are associated with increases in COX-2 activity at the site of origin of the pain.
  • NSAIDs Treatment of inflammation in a patient by administration of NSAIDs is well known. These inhibit both isoforms due to their occupancy of the COX active site, preventing access by arachidonic acid.
  • the resulting local inhibition of prostaglandins is believed to be the underlying cause of unwanted gastro-intestinal side effects such as stomach bleeding and ulceration.
  • This is attributed to inhibition of COX-1
  • the isoform COX-2 is the one closely associated with inflammation since it mediates production of prostaglandin.
  • Various selective inhibitors of COX-2 have accordingly been developed, such as celecoxib and rofecoxib, to treat inflammation, with reduced gastro-intestinal side effects.
  • the COX-2 selective inhibitors have been reported to cause different side effects, most notably in the cardiac area.
  • Certain pathophysiological conditions including ischemia and hypoxia, are associated with increased expression of COX-2 in the brain. It has been shown that topical administration of lipopolysaccharide (LPS) caused a time- dependant dilatation of cerebral arterioles that was inhibited by the selective COX-2 inhibitor NS-398 (Brian JE Jr. et al, Stroke 1998 29:2600-6). Vasodilatation is one of the cardinal manifestations of inflammation in the brain. In an experimental model of brain inflammation COX-2 was shown to be expressed in endothelial cells and it has been suggested that it plays a role in the development of fever during brain inflammation (Cao C et al, J Neurosci 1999 19:716-25).
  • LPS lipopolysaccharide
  • COX-2 has also been suggested to be the key element controlling the generation of proinflammatory mediators involved in the progression of Alzheimer's disease (AD).
  • AD Alzheimer's disease
  • rofecoxib was shown to significantly reverse LPS-induced retention deficit.
  • LPS is known to induce the in vivo synthesis and release of inflammatory mediators such as IL-1 , IL-6 and PGE 2 (Jain NK et al, 2002 Behavioural Brain Research 133:369-376).
  • Inhibitors of COX-2 have also been shown to be effective as therapeutic agents in experimental autoimmune neuritis.
  • a procedure or composition which, when administered to mammalian patients, modulates the expression of the COX-2 gene should, therefore, provide a basis for a treatment or inhibition of the progression of a variety of inflammatory and pain-causing disorders in mammalian patients and of the pain associated therewith. It is an object of the present invention to provide a composition and a method for treating a mammalian subject, to modulate pathological COX-2 activity, and thereby alleviate COX-2-related disorders, with reduced adverse side effects.
  • a cyclooxygenase-related pain-causing disorder in a mammalian subject can be alleviated by reducing the pathological expression of the COX-2 gene in the mammalian patient, by administration thereto of bodies, such as liposomes, beads or similar particles, of a size and conformation resembling mammalian apoptotic cells or apoptotic bodies, and which carry as a major component on their surface at least one phospholipid having as exteriorly presented head groups phosphato glycerol and synthetic mimetics thereof.
  • bodies such as liposomes, beads or similar particles, of a size and conformation resembling mammalian apoptotic cells or apoptotic bodies, and which carry as a major component on their surface at least one phospholipid having as exteriorly presented head groups phosphato glycerol and synthetic mimetics thereof.
  • the lipid portion of the phospholipid can be chosen from a wide rage of fatty acids, saturated and unsaturated, for example dioleyl, distearoly, dipalmitoyl, oleyl-stearoyl, oleyl-palmitoly, stearoyl-palmitoyl, etc, of approproiate carbon chain length, as commonly found in phospholipids. They can be synthetic or natural products. Preferred examples are phospholipids selected from phosphatidylglycerol, distearoylphosphatidylglycerol and dipalmitoylphosphatitidylglycerol.
  • the bodies may carry, as a minor component on their surface, an inactive constituent.
  • compositions of matter useful in inhibiting COX-2 expression in a mammalian patient following administration thereto comprising: pharmaceutically acceptable bodies having a three-dimensional core, of conformation and size corresponding to mammalian apoptotic cells and/or apoptotic bodies, said bodies having a COX-2 expression inhibiting amount of a ligand comprising a phospholipid having a phosphato glycerol head group expressed or expressible on the surface thereof.
  • a process for treating a mammalian patient to alleviate the symptoms of a COX-2 related disorder which comprises administering to the patient a COX-2 expression inhibiting amount of pharmaceutically acceptable bodies having a three-dimensional core, of conformation and size corresponding to mammalian apoptotic cells and/or apoptotic bodies, said bodies having a COX-2 expression inhibiting amount of a ligand comprising a phospholipid having a phosphato glycerol head group expressed or expressible on the surface thereof.
  • a further aspect of the invention provides use, in the manufacture of a medicament for administration to mammalian patients for alleviating the symptoms of a COX-2 related disorder, of pharmaceutically acceptable bodies having a three-dimensional core, of conformation and size corresponding to mammalian apoptotic cells and/or apoptotic bodies, said bodies having a COX- 2 expression inhibiting amount of a ligand comprising a phospholipid having a phosphato glycerol head group expressed or expressible on the surface thereof.
  • Figure 1 shows the mRNA levels of cyclooxygenase (COX)-2 measured by a semi-quantitative polymerase chain reaction (PCR) method in a macrophage established cell line system, Example 1 below.
  • COX cyclooxygenase
  • Preferred phospholipids for use in the present invention are selected from phosphatidylglycerol, distearoylphosphatidyglycerol and dipalmitoylphosphatidyglycerol.
  • the invention from one aspect is directed to a composition
  • a composition comprising bodies having a three-dimensional core structure of conformation and size corresponding to mammalian apoptotic cells and /or bodies and expressing or expressible on the surface thereof phosphato glycerol head group-containing ligands which are chosen so as to interact with certain receptors on the cells of the mammalian body, on administration to a mammalian patient, with the result that the COX-2 expression in the patient is modulated.
  • “Modulating” is defined to mean reducing, physiologically restoring, normalizing or controlling.
  • compositions of the present invention initiate a series of events in the immune system of the mammalian body. While it is not intended that the present invention should be limited by any particular theory of its mechanism or mode of action, it is believed that the bodies of the composition are phagocytosed by antigen presenting cells (APCs) of the immune system with consequent alteration of the cytokine profile of the APCs in favour of COX-2 expression reduction.
  • APCs antigen presenting cells
  • COX-2 modulation effected by the present invention may be the result of analgesic mechanisms in the patient's body. Accordingly, the compositions of the invention are indicated for us in analgesia, pain management and anti-pruritic therapy.
  • “Analgesia” is defined as alleviation of pain, acute and chronic, induced by all known mechanisms, including but not limited to pain related to postoperative pain, cancer, neuropathic pain, and complex regional pain syndrome.
  • Another preferred embodiment is a method for treating noninflammatory related pain involving excessive COX-2 expression in a mammalian patient comprising administering to a mammalian patient a non- toxic, effective, excessive-COX-2-expression- treating amount of liposomal or non-liposomal bodies as defined above, wherein the pain is inhibited and/or reduced.
  • three-dimensional body portions include liposomes, solid beads, hollow beads, filled beads, particles, granules, microspheres, or beads of biocompatible materials, natural or synthetic, such as polyethylene glycol, polyvinylpyrrolidone, polystyrene, poly(methylmethacrylate), etc., polysaccharides such as hydroxyethyl starch, hydroxyethylcellulose, agarose and the like, as commonly used in the pharmaceutical industry.
  • the beads may be solid or hollow, or filled with biocompatible material.
  • These synthetic and semi-synthetic bodies are three dimensional bodies having shapes and dimensions ranging from those resembling mammalian cells to shapes and dimensions approximating to apoptotic bodies produced by the apoptosis of mammalian cells (typically but not exclusively spheroidal, cylindrical, ellipsoidal, including oblate and prolate spheroidal, serpentine, reniform etc., and having diameters of about 20 nanometres to about 500 microns), and having COX-2 expression reducing phosphato-glycerol containing ligands on the surface thereof.
  • compositions of matter are liposomes; which may be composed of a variety of lipids.
  • Liposomes, or lipid vesicles are sealed sacs, in the micron or sub-micron range, the walls of which consist of suitable amphiphiles. They normally contain an aqueous medium.
  • Liposomes are vesicles which can be unilamellar (single membrane) or multi-lamellar (onionlike structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer).
  • the bilayer is composed of two lipid monolayers having a hydrophobic "tail” region and a hydrophilic "head” region.
  • the hydrophobic (nonpolar) "tails” of the lipid monolayers orient toward the center of the bilayer, whereas the hydrophilic (polar) "heads” orient toward the aqueous phase.
  • the liposomes are composed of phosphatidylglycerol, distearoylphosphatidylglycerol, and dipalmitoylphosphatidylglycerol. Such liposomes are prepared and treated so that the active polar head groups are presented exteriorly on the liposomal body. .
  • the diameter of the ligand-carrying liposomes of the preferred embodiment of this invention is from about 20 nanometers to about 500 microns, more preferably from about 20 nanometers to about 1000 nanometers, more preferably from about 50 nanometers to about 500 nanometers, and most preferably from about 80 nanometers to about 120 nanometers.
  • Such preferred diameters will generally correspond to the diameters of mammalian apoptotic bodies or apoptotic cells (typically from 20 nanometres to 500 microns in diameter as measured along the longest axis).
  • biocompatible non-liposomal synthetic bodies when biocompatible non-liposomal synthetic bodies are chosen for use, these may be selected from polysaccharides such as hydroxyethylcellulose, hydroxyethyl starch, agarose; or from non-polysaccharide materials such as polyethylene glycol, poly(methylmethacrylate), polyvinylpyrrolidone, polystyrene and a wide range of other natural, semi-synthetic and synthetic materials.
  • polysaccharides such as hydroxyethylcellulose, hydroxyethyl starch, agarose
  • non-polysaccharide materials such as polyethylene glycol, poly(methylmethacrylate), polyvinylpyrrolidone, polystyrene and a wide range of other natural, semi-synthetic and synthetic materials.
  • Suitable substances for derivatization to attach the phospholipid(s) to three-dimensional bodies are commercially available e.g. from Polysciences Inc., 400 Valley Road, Warrington, PA 18976, or from Sigma Aldrich Fine Chemicals.
  • this invention is directed to lyophilized or freeze-dried bodies carrying such anti-inflammatory promoting ligands, and kits comprising lyophilized or freeze dried bodies carrying such anti-inflammatory promoting ligands and a pharmaceutically acceptable carrier.
  • the three-dimensional bodies as defined above have one or more ligands selected from phosphato glycerol head groups, preferably selected from phosphatidylglycerol, distearoylphosphatidylglycerol and dipalmitoylphosphatidylglycerol on the exterior surface in a manner, in one embodiment, that they are believed to be capable of interacting with the appropriate receptor(s), on antigen presenting cells in vivo, with resulting modulation of expression of COX-2 in the mammalian patient, following administration thereto.
  • the structure of these ligands may be synthetically altered and include all, part of or a modified version of the original ligand.
  • a preferred embodiment of this invention provides synthetic or semi-synthetic bodies carrying anionic and other phospholipids ligands on their surface, namely liposomes or non-liposomal bodies which expose or can be treated or induced to expose on their surface phosphato glycerol head groups, preferably phosphatidylglycerol, distearoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, and the use thereof in treating COX-2 and pain-inducing disorders in mammalian patients.
  • the structure of these ligands may be synthetically altered and include all, part of or a modified version of the original ligand.
  • the preferred phospholipid for use in the present invention is phosphatidylglycerol optionally with a minor portion (up to less than 50% by weight) of another, inactive constituent.
  • the preferred liposome is one constituted to the extent of about 50-100% by weight of phosphatidylglycerol (PG), the balance being phosphatidylcholine (PC) or other such biologically acceptable phospholipid(s). More preferred are liposomes constituted to the extent of 65-90% by weight, most preferably 70-80% by weight, with the single most preferred embodiment being about 75% by weight of active phospholipids, the balance being the other inactive phospholipids such as PC.
  • PG phosphatidylglycerol
  • PC phosphatidylcholine
  • More preferred are liposomes constituted to the extent of 65-90% by weight, most preferably 70-80% by weight, with the single most preferred embodiment being about 75% by weight of active phospholipids, the balance being the other inactive phospholipids such
  • bodies having a mixture of the aforementioned phospholipids having chemically active head groups comprising at least 10%, preferably at least 50% and most preferably 60-90% of the aforementioned active phospholipids.
  • Analogues of phosphatidylglycerol with modified active head groups which also interact with the PG receptors on the antigen presenting cells, or otherwise result in a COX-2 expression modulation reaction in the recipient body, are contemplated within the scope of the term phosphatidylglycerol.
  • the patient may be a mammal, including but not limited to humans and domestic animals such as cows, horses, pigs, dogs, cats and the like.
  • Phospholipids are amphiphilic molecules (i.e. amphiphiles), meaning that the compound comprises molecules having a polar water-soluble group attached to a water-insoluble hydrocarbon chain.
  • the amphiphiles serving as the layers of the matrix have defined polar and apolar regions.
  • the amphiphiles can include in addition to the phospholipids providing the active head groups in the process of the invention, other, naturally occurring lipids used alone with the phospholipid carrying the active head group, or in a mixture with another.
  • the amphiphiles serving as the layer(s) of the liposomes can be inert, structure-conferring synthetic compounds such as polyoxyethylene alkylethers, polyoxyethylene alkylesters and saccharosediesters.
  • the ligand-carrying bodies may be suspended in a pharmaceutically acceptable carrier, such as physiological sterile saline, sterile water, pyrogen-free water, isotonic saline, and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations.
  • a pharmaceutically acceptable carrier such as physiological sterile saline, sterile water, pyrogen-free water, isotonic saline, and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations.
  • the ligand-carrying bodies are constituted into a liquid suspension in a biocompatible liquid such as buffered saline and administered to the patient in any appropriate route which introduces it to the immune system, such as intra-arterially, intravenously, intra-dermally, or most preferably intramuscularly or subcutaneously.
  • the ligand-carrying bodies may be freeze-dried or lyophilized so that they may be later resuspended for administration.
  • a protectant such as sucrose or trehalose is preferably included in any such freeze-dried composition, to protect the liposomes from damage on re- suspension.
  • This invention is also directed to a kit of parts comprising lyophilized or freeze-dried ligand-carrying bodies and a pharmaceutically acceptable carrier, such as physiological sterile saline, sterile water, pyrogen-free water, isotonic saline, and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations.
  • a preferred manner of administering the ligand-carrying bodies to the patient is a course of injections, administered daily, several times per week, weekly or monthly to the patient, over a period ranging from a week to several months.
  • the frequency and duration of the course of the administration is likely to vary from patient to patient, and according to the condition being treated, its severity, and whether the treatment is intended as prophylactic, therapeutic or curative. Its design and optimization is well within the skill of the attending physician.
  • Intramuscular injection is most preferred.
  • One particular injection schedule, in at least some of the indications of the invention is an injection of an appropriate amount of bodies on day 1 , a further injection on day 2, a further injection on day 14, and then "booster" injections at monthly intervals.
  • ligand-carrying bodies to be administered will vary depending on the nature of the mammalian disorder it is intended to treat and on the identity and characteristics of the patient. It is important that the effective amount of ligand-carrying bodies is non-toxic to the patient, and is not so large as to overwhelm the immune system.
  • ligand-carrying bodies When using intra-arterial, intravenous, subcutaneous or intramuscular administration of a liquid suspension of ligand-carrying bodies, it is preferred to administer, for each dose, from about 0.1-50 ml of liquid, containing an amount of ligand-carrying bodies generally equivalent to 10% - 1000%, preferably 10% - 100%, of the number of leukocytes normally found in an equivalent volume of whole blood or the number of apoptotic bodies that can be generated from them.
  • the number of ligand-carrying bodies administered per delivery to a human patient is in the range from about 500 to about 2.5 x 10 12 ( ⁇ 250 ng of bodies, in the case of liposomes, pro-rated for density differences for other embodiments of bodies), more preferably from about 1 ,000 to about 1 ,500,000,000, even more preferably 10,000 to about 100,000,000, and most preferably from about 200,000 to about 20,000,000.
  • the invention is indicated for use with a wide range of disorders associated with an increase in COX-2 activity including, but not limited to pancreatitis, endometriosis, and adenomyosis.
  • the invention is indicated in the inducement of analgesia and the treatment of pain, especially pain unrelated to or not substantially related to inflammation.
  • the source or cause of the pain may include but is not limited to, tissue damage through injury, muscle damage through injury, over-exertion, etc., burns, chemical exposure, toxic substance ingestion or the like, all of which are associated with increases in COX-2 expression at the site of origin of the pain.
  • the invention is indicated for the treatment and prophylaxis of the symptoms of a wide variety of mammalian neuroinfectious diseases including but not limited to meningitis and encephalitis.
  • the compounds of this invention may be administered prior to, in conjunction with or subsequent to administration of a pharmaceutically effective amount of a known COX-2 inhibitor, such as celecoxib (Celebrex ®) or refecoxib (Vioxx®).
  • a pharmaceutically effective amount of the COX-2 inhibitor is administered to reduce excessive COX-2 activity.
  • a pharmaceutically effective amount is well known in the art.
  • the present invention is applicable for treatment of substantially any excessive COX-2 expression-related non-inflammatory pain condition.
  • COX-2 is constitutively expressed in neurons. Excessive COX-2 expression may result from cell damage such as physical injury, chemical injury and pressure on body organs resulting from tumour growth or organ enlargement due to malignancies or other disorder.
  • Another example of a disorder well-suited to treatment according to the invention is post-herpetic neuralgia resulting from shingles where extreme pain develops as an after-effect. Persons developing hyperalgesia (extreme sensitivity to pain) are also suitably treated by the invention.
  • Organ linings e.g. of the liver, contain cells with substance P, which is released in association with excessive expression of COX-2 therefrom.
  • substance P substance P
  • bone pressures associated with cancer growths create pain by similar mechanisms.
  • U937 is a monocytic leukemia line that can be differentiated into macrophages by administration of a phorbol ester.
  • LPS lipopolysaccharide
  • the macrophages can be grown in culture medium in the presence of a suspected COX-2 affecting composition, and the expression of RNA or DNA of the COX-2 measured.
  • Liposomes of size 100 ⁇ 20 nanometers were prepared according to standard methods known in the art and had a composition of 75% phosphatidylglycerol (PG), 25% phosphatidylcholine (PC). The stock concentration of liposome was 39.5mM lipid and was diluted to the following final concentrations in the assay:
  • the U937 cells were cultured by growing in RPMI medium (GIBCO BRL)
  • FCS fetal calf serum
  • penicillin/streptomycin at 37°C
  • PBS Phosphate buffered saline
  • the cells were incubated at 37°C, 5% C0 2 . After 18hrs, each culture was
  • COX-2 and GAPDH mRNA were extracted and detected with the reverse transcription-polymerase chain reaction as (RT-PCR) and carried out using standard methods known in the art (Adderley SR, Fitzgerald DJ, J Biol Chem, Vol.274, Issue 8, 5038-5046, February 19, 1999). The reaction was performed using the following primers:
  • Antisense 5' CAT CAT CAG ACC AGG CAC CAG 3'
  • the GADPH was included as an experimental control to allow for the rough quantitation of COX-2 in the assay.
  • Lane 1 on gel contains markers that confirm the size of the COX-2/GADPH bands. There is a constant band in all lanes of the GADPH gel as this is a housekeeping gene and provides a control for the loading of the gel.
  • the control lane indicates those cells that were not treated with LPS and shows a very low level of COX-2 expression. LPS treatment causes a measurable increase in COX-2 mRNA production (lane 3) when compared with control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

On parvient à soulager les affections inflammatoires et causant la douleur associées à la cyclooxygénase chez un sujet mammalien par la réduction de l'expression pathologique du gène COX-2 chez le patient mammalien grâce à l'administration de corps tels que liposomes, billes ou particules similaires dont la taille et la forme ressemblent à celles des cellules apoptotiques mammaliennes ou des corps apoptotiques, et qui transportent à leur surface, en tant que composant principal, au moins un phospholipide possédant des groupes de tête présentés à l'extérieur des leurs éléments mimétiques synthétiques ou de glycérol.
PCT/CA2003/001622 2002-10-25 2003-10-24 Regulation de cyclooxygenase avec des liposomes pg WO2004037270A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003275842A AU2003275842A1 (en) 2002-10-25 2003-10-24 Cyclooxygenase regulation with pg liposomes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42200302P 2002-10-25 2002-10-25
US60/422,003 2002-10-25

Publications (1)

Publication Number Publication Date
WO2004037270A1 true WO2004037270A1 (fr) 2004-05-06

Family

ID=32176741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001622 WO2004037270A1 (fr) 2002-10-25 2003-10-24 Regulation de cyclooxygenase avec des liposomes pg

Country Status (2)

Country Link
AU (1) AU2003275842A1 (fr)
WO (1) WO2004037270A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082688A1 (fr) * 2003-03-20 2004-09-30 Vasogen Ireland Limited Agonistes et antagonistes de recepteur de phosphatidylglycerol (pg)
WO2005007169A3 (fr) * 2003-07-21 2005-09-22 Vasogen Ireland Ltd Traitement de conditions inflammatoires aigues

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011781A1 (fr) * 1989-04-04 1990-10-18 Alcon Laboratories, Inc. Utilisation de liposomes pour l'apport d'agents therapeutiques a des blessures, des coupures et abrasions
WO2001003668A1 (fr) * 1999-07-08 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Administration pulmonaire de cannabinoides encapsules dans des liposomes
WO2002005848A2 (fr) * 2000-07-13 2002-01-24 Pharmacia Corporation Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
WO2003015698A2 (fr) * 2001-08-13 2003-02-27 University Of Pittsburgh Application de vehicules lipidiques et utilisation dans le cadre de l'administration de medicaments
WO2003086351A1 (fr) * 2002-04-05 2003-10-23 Esperion Luv Development, Inc. Compositions et procedes de dosage de liposomes de certaines tailles pour traiter ou prevenir une maladie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011781A1 (fr) * 1989-04-04 1990-10-18 Alcon Laboratories, Inc. Utilisation de liposomes pour l'apport d'agents therapeutiques a des blessures, des coupures et abrasions
WO2001003668A1 (fr) * 1999-07-08 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Administration pulmonaire de cannabinoides encapsules dans des liposomes
WO2002005848A2 (fr) * 2000-07-13 2002-01-24 Pharmacia Corporation Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
WO2003015698A2 (fr) * 2001-08-13 2003-02-27 University Of Pittsburgh Application de vehicules lipidiques et utilisation dans le cadre de l'administration de medicaments
WO2003086351A1 (fr) * 2002-04-05 2003-10-23 Esperion Luv Development, Inc. Compositions et procedes de dosage de liposomes de certaines tailles pour traiter ou prevenir une maladie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANNON G W: "Rofecoxib: a specific cyclooxygenase inhibitor.", DRUGS OF TODAY (BARCELONA, SPAIN: 1998) SPAIN APR 2000, vol. 36, no. 4, April 2000 (2000-04-01), pages 255 - 262, XP009025825, ISSN: 0025-7656 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082688A1 (fr) * 2003-03-20 2004-09-30 Vasogen Ireland Limited Agonistes et antagonistes de recepteur de phosphatidylglycerol (pg)
WO2005007169A3 (fr) * 2003-07-21 2005-09-22 Vasogen Ireland Ltd Traitement de conditions inflammatoires aigues

Also Published As

Publication number Publication date
AU2003275842A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
JP6305973B2 (ja) 非ステロイド性抗炎症薬の徐放性処方物
US20180008629A1 (en) Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
Xu et al. Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis
EP1196161B1 (fr) Acide linoleique conjuge pour le traitment de l'inflammation et des douleurs mediees par la cyclooxygenase-2
EP2039355A2 (fr) Utilisation topique d'acide valproïque pour la prévention ou le traitement de troubles de la peau
AU2018307509A1 (en) Liposome compositions comprising weak acid drugs and uses thereof
JP7381471B2 (ja) 脱髄疾患の治療
JP2001512418A (ja) 遅効性及び／又は徐放性ビタミンｄ製剤を用いる前立腺疾患の治療方法
JP2004508423A (ja) ホスファチジルセリンを保有するアポトーシス擬態体及び医療用治療におけるその使用
JP2009501168A (ja) Ｎｓａｉｄとして作用する化合物との併用でのヒストン脱アセチル化酵素阻害剤のヒト疾患治療のための使用
Morris et al. Nonsteroidal anti-inflammatory agents in neonates
Hopewell et al. The modulation of radiation-induced damage to pig skin by essential fatty acids
JP2005515242A (ja) リン脂質本体ならびに炎症性疾患および自己免疫疾患の処置におけるその使用
FR2904554A1 (fr) Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients proteurs de cancers multiples
AU2020239829A1 (en) Oral rapamycin nanoparticle preparations and use
Tunçtan et al. Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis
WO2004037270A1 (fr) Regulation de cyclooxygenase avec des liposomes pg
WO2004037271A1 (fr) Regulation de la cyclooxygenase au moyen de phosphatidylcholine liposomes
CN112040935B (zh) 诱导哺乳动物饱腹感的方法
Bose et al. Biomimetic nanomaterials for the immunomodulation of the cardiosplenic axis postmyocardial infarction
Li et al. Silica-induced ferroptosis activates retinoic acid signaling in dendritic cells to drive inflammation and fibrosis in silicosis
US20050058698A1 (en) Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease
US20070042953A1 (en) Antiepileptogenic complex of albumin with docosahexaenoate
US20240293333A1 (en) Topical delivery of lipoprotein-mimetic nanoparticles
Patra Micturition in normal and hypertensive conscious rat: sex difference in cyclooxygenase inhibition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载